Article
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2017
Kakavand Hojabr, Rawson Robert V, Pupo Gulietta M, Yang Jean Y H, Menzies Alexander M, Carlino Matteo S, Kefford Richard F, Howle Julie R, Saw Robyn P M, Thompson John F, Wilmott James S, Long Georgina V, Scolyer Richard A, Rizos Helen
Abstract excerpt
Purpose: To examine the relationship between immune activity, PD-L1 expression, and tumor cell signaling, in metastatic melanomas prior to and during treatment with targeted MAPK inhibitors.Experimental Design: Thirty-eight tumors from 17 patients treated with BRAF inhibitor (n = 12) or combination BRAF/MEK inhibitors (n = 5) with known PD-L1 expression were analyzed. RNA expression arrays were performed on all...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.